SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

   Biotech / MedicalAYTU (MC $16 M) (Cash $11.8 M) 4 Marketed Products +Big Drug


Previous 10 Next 10 
From: BioHero10/18/2017 9:50:30 AM
   of 20
 
Stock almost up 100% in last day and up today again

AYTU will start trading on Nasdaq this week
finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan1/14/2018 3:08:02 PM
   of 20
 
Jan. 12 . Up 0.40 .. +17% closed at $2.80 .. vol. 252k

stockcharts.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/8/2019 1:22:39 PM
   of 20
 
Aytu BioScience Reports 71% Revenue Growth in Q2 FY19

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/8/2019 1:23:40 PM
   of 20
 
Aytu BioScience Announces ZolpiMist (TM) Global Distribution Agreement with SUDA Pharmaceuticals

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/19/2019 1:23:35 PM
   of 20
 
Aytu BioScience Announces Two Recent Publications Highlighting Improved Efficacy and Patient Preference of Natesto Nasal Testosterone over Topical Gels

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/28/2019 4:07:53 PM
   of 20
 
Aytu BioScience Provides Study Update for Spermatogenesis Study of Natesto (R), the Only FDA-Approved, Nasally-Administered Testosterone Treatment

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan9/13/2019 1:43:38 AM
   of 20
 
Aytu BioScience Announces Definitive Agreement to Acquire Innovus Pharmaceuticals

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Sultan2/14/2020 2:23:08 AM
   of 20
 
Aytu BioScience's (AYTU) CEO Josh Disbrow on Q2 2020 Results - Earnings Call Transcript

seekingalpha.com

Share RecommendKeepReplyMark as Last Read


From: Sultan3/10/2020 1:36:07 PM
   of 20
 
What a move today on crazy volume ..

Aytu BioScience Secures Exclusive U.S. Distribution Agreement for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test

finance.yahoo.com

Share RecommendKeepReplyMark as Last Read


From: Giants19673/19/2020 11:12:02 AM
   of 20
 
AYTU Aytu BioScience Expands Its Distribution Rights for Coronavirus 2019 (COVID-19) Point-of-Care Rapid Test to Canada and Mexico Company Expects to Seek Regulatory Clearance Under Health Canada and COFEPRIS Expedited Clearance Procedures.

Aytu BioScience, Inc. (NASDAQ:AYTU), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it extended its distribution right to commercialize the clinically validated and commercially used coronavirus 2019 (COVID-19) IgG/IgM Rapid Test. The test has been licensed from L.B. Resources, Limited (a Hong Kong Corporation). The COVID-19 IgG/IgM Rapid Test is intended for professional use and delivers clinical results between 2 and 10 minutes at the point-of-care. This amendment expands Aytu's commercial rights and grants Aytu the right to distribute and commercialize the COVID-19 test in North America, specifically including the United States, Canada and Mexico.

The Company expects to pursue expedited regulatory clearance of the product with Health Canada and COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios), the regulatory agencies in Canada and Mexico, respectively.

Josh Disbrow, Chief Executive Officer of Aytu BioScience, commented, "We have to be progressive in doing our part in combatting the spread of the COVID-19 virus. We need to ensure that screening is available across North America and providing broad access to screening tests has to be among our highest priorities as we collectively fight the coronavirus outbreak. With COVID-19 now designated as a global pandemic, we believe we should expand our efforts to assist healthcare providers with faster point-of-care detection."

The COVID-19 IgG/IgM Rapid Test is a solid phase immunochromatographic assay used in the rapid, qualitative and differential detection of IgG and IgM antibodies to the 2019 Novel Coronavirus in human whole blood, serum or plasma. This point-of-care test has been validated in a 113 patient clinical trial and is CE marked.

Share RecommendKeepReplyMark as Last ReadRead Replies (1)
Previous 10 Next 10